Overall survival ranged from 6.0 to 25.3 months, with a median follow-up of 18.3 months since the initiation of BRAF and MEK inhibitors.<h4>Conclusions</h4>This case series highlights the potential benefits and challenges of targeted therapies in advanced thyroid cancer. The gene discussed is MAP2K7; the disease is thyroid gland carcinoma.